Going Concern (worsened) — Going concern language now explicitly states 'substantial doubt' with near and long term cash requirements insufficient for next twelve months.
Delisting (worsened) — Company received new Nasdaq deficiency notice in April 2026 for negative stockholders' equity of $1.55M, escalating from prior compliance issues.

NASDAQ: VVOS Vivos Therapeutics, Inc. 10-Q

Vivos posts 70% revenue growth from sleep services acquisition but losses double to $7.8M

Filed May 20, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade VVOS commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · May 25, 2026 7:10 AM